X

Trial Profile

A Phase IIa clinical study to evaluate the safety and efficacy of afamelanotide in arterial ischaemic stroke (AIS)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afamelanotide (Primary)
Indications Stroke
Focus Adverse reactions; Therapeutic Use
Acronyms CUV801
Sponsors Clinuvel Pharmaceuticals

Most Recent Events

30 Oct 2020 New trial record
28 Oct 2020 According to a Clinuvel Pharmaceuticals media release, this study will be conducted at a single expert neurological emergency centre. First results from the study are expected in the first half of 2021, depending on the capacity of hospitals due to the COVID pandemic.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com